Abeona Therapeutics Inc
Follow $ABEO
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $ABEO by emailVeridion Score
BETAHIGH CONF · 6 of 6 factors measuredHighest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is ABEO moving today?
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
ABEO overview
Related filings and maps
Congress activity in ABEO
No receipt-qualified Congressional disclosure is present for ABEO in the cached public ledger.
ABEO contract awards, year to date.
Public federal awards linked to this ticker.
ABEO lobbying filings, year to date.
Registered lobbying filings matched to Abeona Therapeutics Inc.